Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Chiara Martini
Based on 3 articles published since 2009
(Why 3 articles?)

Between 2009 and 2019, Chiara Martini wrote the following 3 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Review Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. 2019

Altieri, Barbara / Di Dato, Carla / Martini, Chiara / Sciammarella, Concetta / Di Sarno, Antonella / Colao, Annamaria / Faggiano, Antongiulio / Anonymous5721562. ·Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy. altieri.barbara@gmail.com. · Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Wuerzburg, 97080 Wuerzburg, Germany. altieri.barbara@gmail.com. · Department of Clinical Medicine, Bufalini Hospital, 47521 Cesena, Italy. didatocarla@gmail.com. · Clinica Medica 3, Department of Medicine, DIMED, University of Padova, 35128 Padova, Italy. chiara.martini@aopd.veneto.it. · Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, 37126 Verona, Italy. concetta.sciammarella@alice.it. · UOC of Oncology, AO dei Colli, Monaldi Unit, 80131 Naples, Italy. antonella.disarno@gmail.com. · Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy. colao@unina.it. · Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy. antongiulio.faggiano@uniroma1.it. · Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy. ·Cancers (Basel) · Pubmed #31500357.

ABSTRACT: Bone represents a common site of metastases for several solid tumors. However, the ability of neuroendocrine neoplasms (NENs) to localize to bone has always been considered a rare and late event. Thanks to the improvement of therapeutic options, which results in longer survival, and of imaging techniques, particularly after the introduction of positron emission tomography (PET) with gallium peptides, the diagnosis of bone metastases (BMs) in NENs is increasing. The onset of BMs can be associated with severe skeletal complications that impair the patient's quality of life. Moreover, BMs negatively affect the prognosis of NEN patients, bringing out the lack of curative treatment options for advanced NENs. The current knowledge on BMs in gastro-entero-pancreatic (GEP) and bronchopulmonary (BP) NENs is still scant and is derived from a few retrospective studies and case reports. This review aims to perform a critical analysis of the evidence regarding the role of BMs in GEP- and BP-NENs, focusing on the molecular mechanisms underlining the development of BMs, as well as clinical presentation, diagnosis, and treatment of BMs, in an attempt to provide suggestions that can be used in clinical practice.

2 Review The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma? 2018

Guarnotta, Valentina / Martini, Chiara / Davì, Maria Vittoria / Pizza, Genoveffa / Colao, Annamaria / Faggiano, Antongiulio / Anonymous10670923. ·Biomedical Department of Internal and Specialist Medicine (DIBIMIS), Section of Endocrine-Metabolic Diseases, University of Palermo, Palermo, Italy. · Clinica Medica 3^, Department of Medicine, DIMED, University of Padova, Padova, Italy. chiara.martini@aopd.veneto.it. · Section of Endocrinology, Medicina Generale e Malattie Aterotrombotiche e Degenerative, Department of Medicine, University of Verona, Verona, Italy. · Department of Clinical Medicine and Surgery, "Federico II" University of Naples, Naples, Italy. · Thyroid and Parathyroid Surgery Unit, Istituto Nazionale per lo studio e la cura dei tumori "Fondazione G. Pascale" - IRCCS, Naples, Italy. ·Endocrine · Pubmed #29019150.

ABSTRACT: PURPOSE: Analyze the role of somatostatin analogues (SSAs) in the treatment of sporadic and MEN1-related gastrinomas, trying to define whether recent trials have changed the landscape of gastrinoma therapy. METHODS: We evaluate the rationale of SSA use in the treatment of gastrinomas, summarize the current literature concerning the effect of SSAs on the control of Zollinger-Ellison syndrome (ZES) and gastrinomas tumor progression and discuss their role in the most recent guidelines. RESULTS: The medical treatment of gastrinoma and related ZES is aimed at controlling acid hypersecretion and tumor progression, in inoperable patients. The use of proton pump inhibitors (PPIs) to control the syndrome is a cornerstone in the ZES therapy. SSAs are not usually indicated for antisecretory purpose, because PPIs are considered the treatment of choice, due to their long lasting high efficacy and oral availability. The antiproliferative effect of SSAs has been established by two placebo-controlled trials that have clearly demonstrated a significant increase in progression free survival in patients affected by non-functioning well-differentiated advanced neuroendocrine tumors (NETs). The recent ENETS guidelines recommend the use of SSAs in advanced well differentiated NETs as antiproliferative agents. CONCLUSIONS: The high sstr-expression in gastrinomas make them highly responsive to SSAs and support the use of such drugs to counteract the tumour growth in patients not amenable to surgical cure. Unfortunately, limited data, mainly case reports or small series, support the use of SSAs in advanced gastrinomas, therefore, it is difficult to quantify their ability to control tumour growth and disease progression.

3 Article Ovarian tumors secreting insulin. 2015

Battocchio, Marialberta / Zatelli, Maria Chiara / Chiarelli, Silvia / Trento, Mariangela / Ambrosio, Maria Rosaria / Pasquali, Claudio / De Carlo, Eugenio / Dassie, Francesca / Mioni, Roberto / Rebellato, Andrea / Fallo, Francesco / Degli Uberti, Ettore / Martini, Chiara / Vettor, Roberto / Maffei, Pietro. ·Internal Medicine 3, Department of Medicine, University of Padua, Via Giustiniani 2, 35100, Padua, Italy, marialberta@hotmail.it. ·Endocrine · Pubmed #25896552.

ABSTRACT: Combined ovarian germ cell and neuroendocrine tumors are rare. Only few cases of hyperinsulinism due to ovarian ectopic secretion have been hypothesized in the literature. An ovarian tumor was diagnosed in a 76-year-old woman, referred to our department for recurrent hypoglycemia with hyperinsulinism. In vivo tests, in particular fasting test, rapid calcium infusion test, and Octreotide test were performed. Ectopic hyperinsulinemic hypoglycemia was demonstrated in vivo and hypoglycemia disappeared after hysteroadnexectomy. Histological exam revealed an ovarian germ cell tumor with neuroendocrine and Yolk sac differentiation, while immunostaining showed insulin positivity in neuroendocrine cells. A cell culture was obtained by tumoral cells, testing Everolimus, and Pasireotide. Insulin was detected in cell culture medium and Everolimus and Pasireotide demonstrated their potentiality in reducing insulin secretion, more than controlling cell viability. Nine cases of hyperinsulinism due to ovarian ectopic secretion reported in literature have been reviewed. These data confirm the ovarian tissue potentiality to induce hyperinsulinemic hypoglycemic syndrome after neoplastic transformation.